INDUCTION OF SEVERE AUTOIMMUNE DISEASE IN
NORMAL MICE BY SIMULTANEOUS ACTION OF
MULTIPLE IMMUNOSTIMULATORS

By LEMING HANG, M. TERESA AGUADO, FRANK J. DIXON, AND
ARGYRIOS N. THEOFILOPOULOS

From the Department of Immunology, Scripps Clinic and Research Foundation,
La Jolla, California 92037

Mice with late-life systemic lupus erythematosus (SLE) backgrounds develop
early, severe disease when subjected to various accelerating factors. Similar
immunostimulation of normal mice leads to relatively innocuous autoimmune
responses (1–4).

This study asks the following questions: (a) Can the resistance of immunolog-
ically normal mice to immunostimulation and pathogenic autoimmune responses
be overcome by simultaneous action of multiple qualitatively different immuno-
stimulating factors, and (b) if so, what features distinguish the pathogenic vs.
nonpathogenic autoimmune responses? We found that any single accelerating
factor can enhance the underlying autoimmune diseases in genetically predis-
posed mice, but simultaneous stimulation by multiple accelerating factors is
required to induce pathogenic autoimmune responses in immunologically normal
mice. The severity of pathogenic autoimmune responses correlates best with the
total quantities of circulating immune complexes (CIC) and the fine characteris-
tics of the autoantibodies rather than the magnitudes or multitudes of autoim-
mune responses elicited.

Materials and Methods

MRL-lpr/lpr (lymphoproliferation gene homozygotes; MRL-lpr), C57BL/6-lpr/lpr (B6-
lpr), and C3H/HeJ-lpr/lpr (C3H-lpr) female mice were originally developed at The
Jackson Laboratory (Bar Harbor, ME) (1) and bred further at the Scripps Mouse Colony.
The non-lpr congenic MRL/n, B6, and C3H/HeJ mice were bred and maintained at the
Scripps Mouse Colony. Groups of 15 female mice of the three lpr substrains and their
non-lpr congenic strains were studied.

Five groups of mice (two lpr strains, B6-lpr and C3H-lpr, and three non-lpr strains,
MRL/n, B6, C3H/HeJ) were injected intraperitoneally with the lipid-A portion of lipo-
poly saccharide (LPS) (R595, purified from Salmonella minnesota; Calbiochem-Behring
Corp., San Diego, CA) from 6 wk of age until moribund, or up to 10 mo, as previously
described (3). Similar groups of unmanipulated mice served as controls. Histologic and
serologic studies in the above groups of mice were performed as previously described (5,
6).

This is publication number 34381MM from the Department of Immunology, Scripps Clinic and
Research Foundation, 10666 North Torrey Pines Road, La Jolla, CA, 92037. This work was
supported in part by grants AI-07007, AM-31023, and AM33826, from the National Institutes of
Health, and by the Kroc Foundation. L. Hang is recipient of a Lupus Research Institute Scholarship.
M. T. Aguado is recipient of an Arthritis Foundation Postdoctoral Fellowship.

J. Exp. Med. © The Rockefeller University Press • 0022-1007/85/2/0423/06 $1.00
423
Volume 161 February 1985 423–428
TABLE I

Effects of Immunostimulation on Survival and Autoimmune Histopathologic Manifestations in Three Different Murine Strains

| Murine strain background | Mode of immunostimulation | Age of 50% mortality | Lymphoid proliferation | Histopathology |
|-------------------------|--------------------------|----------------------|-----------------------|---------------|
|                         |                          | mo                   | g, g                  | GN, Arthritis |
| MRL/n                   | lpr                      | 5.5                  | 1.9, 0.69             | 5-4+, 2-3*    |
|                         | LPS                      | 6.5                  | <0.1, 0.45            | 5-4+, 0       |
|                         | None                     | 17                   | <0.1, 0.38            | 5-4+, 3-4+    |
| C57BL/6                 | lpr + LPS                | 7.5                  | 1.2, 0.58             | 5-4+, 0       |
|                         | lpr                      | 12                   | 0.8, 0.33             | 1-2+, 0       |
|                         | LPS                      | >12                  | <0.1, 0.38            | 1-2+, 0       |
|                         | None                     | >17                  | <0.1, 0.12            | 0, 0          |
| C3H/HeJ                 | lpr + LPS                | >12                  | 1.8, 0.60             | 0-1+, 0       |
|                         | lpr                      | >12                  | 1.7, 0.38             | 0-1+, 0       |
|                         | LPS                      | >12                  | 0.1, 0.15             | 0, 0          |
|                         | None                     | >17                  | 0.1, 0.14             | 0, 0          |

In each group, autopsies were done on mice that appeared moribund (not necessarily due to GN), or at 12 or 17 mo of age. The degree of lymphoproliferation and severity of histopathology in each group represent average values obtained with 15 mice.

Results

As indicated in Table I, immunostimulation by lpr accelerated the latent disease (glomerulonephritis [GN] and arthritis) of SLE-prone MRL/n mice (50% mortality reduced from 17 to 5.5 mo). In contrast, lpr had much less disease-inducing effect on C57BL/6 and C3H/HeJ mice. Even at 12 mo, these mice had only mild GN and no arthritis, and did not die from kidney failure.

Chronic immunostimulation by LPS accelerated the latent autoimmunity and GN (though not the arthritis) of MRL/n mice (50% mortality at 6.5 mo), but induced much milder SLE in LPS-responding normal mice (B6), and none in LPS-nonresponding normal mice (C3H/HeJ). When subjected to simultaneous lpr and LPS immunostimulation, normal mice (B6) developed early-onset, fatal SLE (50% GN-associated mortality at 7.5 mo).

The total lymphoid mass (at 5 mo), reflecting the degree of lpr-induced lymphoid hyperplasia, was highest in MRL-lpr, followed closely by C3H-lpr mice. B6-lpr mice had less lymphoproliferation, although proliferation increases to comparable levels with age or simultaneous LPS treatment. LPS-induced lymphoproliferation was manifested by weight increases in the spleen, rather than in lymph nodes.

Each of lpr and LPS increased the total IgG in all three strains, except in the case of C3H/HeJ injected with LPS (Table II). In SLE-prone MRL/n mice, lpr induced the highest increases of IgG, particularly IgG1 and IgG2a, while LPS induced smaller increases, predominantly in IgG2b. In the two normal strains, lpr induced a smaller IgG increase, but the increase was in the same IgG subclasses as in MRL. In the LPS responder, B6, the LPS-associated increase was predominantly in the IgG2b subclass. With superimposed LPS stimulation, B6-lpr mice attained IgG levels nearly equivalent to MRL-lpr mice, but the predominant IgG isotype was IgG2b.

In MRL mice, lpr markedly increased the total CIC and specifically increased
levels of retroviral glycoprotein 70 immune complexes (gp 70 IC), whereas LPS induced smaller increases (Table II). In the other two strains, each immunostimulator raised the levels of these two complexes somewhat above unmanipulated controls. In contrast, B6-lpr mice subjected to prolonged LPS stimulation showed significant CIC increases.

Anti-single-stranded DNA autoantibodies in all three lpr strains were increased over non-lpr controls, the highest in lupus-background mice. LPS increased these autoantibodies in the two LPS-responder strains, but not in

| Murine strain background | Mode of immunostimulation | Total IgG | Isotype distribution | Anti-single-stranded DNA binding | gp70 IC | Total CIC |
|-------------------------|---------------------------|-----------|----------------------|---------------------------------|---------|-----------|
|                         |                            |           | igG1 | igG2a | igG2b |               |            |           |
| MRL/n                  | lpr                        | 34        | 56  | 38   | 6     | 88 ± 21       | 16 ± 3     | >400      |
|                        | LPS                        | 14        | 36  | 21   | 45    | 49 ± 12       | 25 ± 6     | 70 ± 22   |
|                        | None                       | 8         | 50  | 32   | 18    | 18 ± 10       | 5 ± 2      | 12 ± 2    |
| C57BL/6                | lpr + LPS                  | 33        | 30  | 24   | 48    | 59 ± 21       | 11 ± 21    | 180 ± 112 |
|                        | lpr                        | 19        | 50  | 39   | 19    | 38 ± 10       | 5 ± 1      | 25 ± 40   |
|                        | LPS                        | 12        | 22  | 7    | 71    | 41 ± 15       | 5 ± 2      | 35 ± 20   |
|                        | None                       | 5         | 50  | 24   | 26    | 6 ± 4         | <1 <4      |           |
| C3H/HeJ                | lpr + LPS                  | 18        | 44  | 36   | 19    | 46 ± 16       | 2 ± 1      | 22 ± 20   |
|                        | lpr                        | 17        | 41  | 39   | 18    | 42 ± 16       | 2 ± 1      | 20 ± 16   |
|                        | LPS                        | 7         | 41  | 34   | 25    | 5 ± 4         | <1 <4      |           |
|                        | None                       | 6         | 47  | 33   | 22    | 6 ± 3         | <1 <4      |           |

Determinations were done in 5-mo-old MRL-lpr and MRL/n mice treated with LPS, 7-mo-old B6-lpr given LPS, and C3H-lpr given LPS, and in 10-mo-old B6-lpr, B6 given LPS, C3H-lpr, and C3H/HeJ mice given LPS. Values represent averages obtained with 15 mice per group.

* Sum of all three IgG subclasses measured by radial immunodiffusion.
* Values expressed as percent of total IgG.
* Values >20 μg/ml were considered positive for IgM RF activity, since such levels are not found in unmanipulated normal mice and other SLE mice lacking the lpr gene.
In MRL-\emph{lpr} mice, most antibodies (70\%) were IgG1 and IgG2a, while they were mostly IgM in young, normal-background \emph{lpr} and LPS-treated non-\emph{lpr} mice. Analysis of 5–10 sera from young and old \emph{lpr} mice revealed that the switch from IgM to IgG anti-single-stranded DNA autoantibodies occurred in 4–5-mo-old MRL-\emph{lpr} mice, but was delayed to 10–12 mo of age in normal-background \emph{lpr} mice (data not shown).

Total IgM and IgM rheumatoid factors (RF) increased in MRL-\emph{lpr} homozygous or normal genetic background mice, and in LPS-responding mice. The \emph{lpr}-induced IgM RF were higher in B6-\emph{lpr} and C3H-\emph{lpr} than in MRL-\emph{lpr} mice (Table III). MRL-\emph{lpr} RF represented 23\% of the total IgM; B6-\emph{lpr} and C3H-\emph{lpr} RF comprised 62 and 59\% of their total IgM, respectively. Interestingly, chronic LPS treatment of B6-\emph{lpr} mice reduced, rather than increased, IgM RF. MRL-\emph{lpr} IgM RF exhibited higher reactivity with the IgG2a substrate, whereas B6-\emph{lpr} and C3H-\emph{lpr} IgM RF had higher anti-IgG1 activity. In the two responder strains, LPS induced polyclonal IgM RF that reacted primarily with IgG1.

Discussion

The main findings of this study are: (a) Genetic background influences the specificities and isotypes of autoimmune responses and the distribution and severity of immunopathology caused by endogenous (\emph{lpr} gene) and/or exogenous immunostimulating factors (LPS), and (b) Synergistic action of multiple immunostimulators can overcome the previously observed (2–5) “resistance” of normal mice to the induction of significant autoimmune disease.

While the \emph{lpr} gene accelerates latent GN and arthritis in SLE-prone MRL/n mice, LPS accelerates GN only. Differences in immunopathology induced by two accelerators acting on the same genetic background might be explained by differences in the cell types stimulated and in the fine characteristics of the resulting immunologic responses. Thus, while the \emph{lpr} gene promotes Thy-1\(^{+}\), Lyt-1\(^{+}\) cell proliferation with enhanced helper activities (7), LPS directly stimulates B cells. Not surprisingly, the hypergammaglobulinemia and specificities of some induced autoantibodies differed. The increased IgG induced by \emph{lpr} was primarily IgG1 and IgG2a, due to their strong T cell dependency (8). In contrast, LPS induced primarily IgG2b. While most RF induced by \emph{lpr} in the MRL/n mice were anti-IgG2a, those stimulated by LPS were almost exclusively anti-IgG1. Complementarity of anti-IgG2a RF with the abundant IgG2a autoantibodies in \emph{lpr} homozygous, lupus-background mice (9) should increase the amount and size of CIC, possibly enhancing their pathogenicity. In contrast, little complementation could occur between RF and autoantibodies in LPS-treated MRL/n mice and, therefore, the complexes formed may be less pathogenic. Moreover, proliferating T cells in MRL-\emph{lpr} mice might have arthritogenic activities and/or, the increased Ia expression detected (10) in macrophages of MRL-\emph{lpr} mice might allow better self-antigen presentation to the T cells infiltrating the synovium, thereby promoting tissue destruction.

In contrast to lupus-prone mice, introduction of \emph{lpr} or LPS into normal-background mice failed to cause significant immunopathology. This was despite the induction of autoantibodies, as previously reported (4, 11). Higher amounts of autoantibodies and IC, and the earlier switch of autoantibodies from IgM to
IgG may account for the severe immunopathology in lupus-prone, but not in normal mice. It is likely that activated B cells in lupus-background mice (7, 12) respond better to proliferation and differentiation factors secreted by the lpr-induced abnormal T cells, thereby allowing a higher number of switching events. The lower levels of IgM RF in MRL-lpr mice (vs. normal-background lpr/lpr mice) may be caused by the removal of MRL-lpr RF from the circulation after coupling with complementary IgG2a autoantibodies, which should not occur as efficiently with the predominantly anti-IgG1 RF of normal-background lpr homozygotes. This possibility is supported by the observations that ~60% of the total IgM in normal-background lpr homozygous mice have RF activity, vs. 23% in MRL-lpr mice.

The novel finding is that two simultaneously administered immunostimulators can overcome the resistance shown by B6 mice to induction of significant autoimmune disease by either stimulator alone. LPS-activated B6-lpr B cells may have an increased ability to receive and respond to lpr-induced antigen-nonspecific differentiation factors, which allows increased polyclonal Ig and autoantibody production above threshold levels. In lupus-background (MRL/n) mice, the apparently increased numbers of spontaneously activated B cells (9, 12) allows them to respond to lpr stimulation alone to attain their pathogenic potentials.

Previous studies (13, 14) indicate that in vivo and in vitro lymphocytes from normal mice secrete autoantibodies spontaneously or after mitogenic stimulation. Idiotypes expressed on autoantibodies from lupus mice are also expressed in normal mice (15) and, conversely, idiotypes of autoantibodies from normal mice can be found in lupus mice (16). Despite this, the idiotype similarities may be only partial, or caused by parallel sets of antibodies without specificities for autoantigens (15), and do not necessarily include pathogenic idiotypes. Our findings indicate that most of the autoantibody variable region gene repertoire is represented in normal-background mice, but needs an appropriate stimulus or combinations of stimuli to be fully expressed. These findings complement recent protein sequencing (17) and molecular cloning (18, 19) experiments which suggest that the structural genetic elements of autoantibodies from lupus mice are closely related to those encoding antibodies to exogenous antigens in normal mice.

Summary

Either of two immunostimulating factors (lpr, lipopolysaccharide) enhanced the pathogenic autoimmune responses of MRL/n mice, but the serologic and immunopathologic characteristics differed. In contrast, either factor, acting alone, caused minimal immunopathology in normal mice, despite autoantibody induction. Combined immunostimulation, however, caused fatal glomerulonephritis in normal-background C57BL/6 mice. These results show the profound influence of the background genome on the effects of immunostimulating agents, and show that resistance to autoimmune disease in immunologically normal mice is not absolute.

References

1. Murphy, E. D. 1981. Lymphoproliferation (lpr) and other single-locus models for murine lupus. In Immunologic Defects in Laboratory Animals. M. E. Gershwin and B. Merchant, editors. Plenum Publishing Co., New York. 143-171.
2. Tonietti, G., M. B. A. Oldstone, and F. J. Dixon. 1970. The effect of induced chronic viral infections on the immunologic disease of New Zealand mice. J. Exp. Med. 132:89.

3. Hang, L., J. H. Slack, C. Amundson, S. Izui, A. N. Theofilopoulos, and F. J. Dixon. 1983. Induction of murine autoimmune disease by chronic polyclonal B cell activation. J. Exp. Med. 157:874.

4. Warren, R. W., S. A. Caster, J. B. Roths, E. D. Murphy, and D. S. Pisetsky. 1984. The influence of the lpr gene on B cell activation: different antibody expression in lpr congenic mouse strains. Clin. Immunol. Immunopathol. 31:65.

5. Hang, L., A. N. Theofilopoulos, and F. J. Dixon. 1982. A spontaneous rheumatoid arthritis-like disease in MRL/1 mice. J. Exp. Med. 155:1690.

6. Theofilopoulos, A. N., R. S. Balderas, L. M. Hang, and F. J. Dixon. 1983. Monoclonal IgM rheumatoid factor derived from arthritic MRL/Mp-lpr/lpr mice. J. Exp. Med. 158:901.

7. Prud'homme, G. J., C. L. Park, T. M. Fieser, R. Kofler, F. J. Dixon, and A. N. Theofilopoulos. 1983. Identification of a B cell differentiation factor(s) spontaneously produced by proliferating T cells in murine lupus strains of the lpr/lpr genotype. J. Exp. Med. 157:730.

8. Isakson, P. C., E. Pure, E. S. Vitetta, and P. H. Krammer. 1982. T cell-derived B cell differentiation factor(s). Effect on the isotype switch of murine B cells. J. Exp. Med. 155:734.

9. Slack, J. H., L. M. Hang, J. Barkley, R. J. Fulton, L. D’Hoostelaere, A. Robinson, and F. J. Dixon. 1984. Isotypes of spontaneous and mitogen-induced autoantibodies in SLE-prone mice. J. Immunol. 132:1271.

10. Kofler, R., R. D. Schreiber, F. J. Dixon, and A. N. Theofilopoulos. 1984. Macrophage I-A/I-E expression and macrophage-stimulating lymphokines in murine lupus. Cell. Immunol. 87:92.

11. Izui, S., V. E. Kelley, M. Kazushige, H. Yoshida, J. B. Roths, and E. D. Murphy. 1984. Induction of various autoantibodies by mutant gene lpr in several strains of mice. J. Immunol. 133:227.

12. Raveche, E. S., A. D. Steinberg, A. L. DeFranco, and J. H. Tjio. 1982. Cell cycle analysis of lymphocyte activation in normal and autoimmune strains of mice. J. Immunol. 129:1219.

13. Pisetsky, D. S., and S. A. Caster. 1982. The B cell repertoire for autoantibody: frequency of precursor cells for anti-DNA antibodies. Cell. Immunol. 72:294.

14. Fish, F., and M. Ziff. 1982. The in vitro and in vivo induction of anti-double-stranded DNA antibodies in normal and autoimmune mice. J. Immunol. 128:409.

15. Datta, S. K., B. D. Stollar, and R. S. Schwartz. 1983. Normal mice express idiotypes related to autoantibody idiotypes of lupus mice. Proc. Natl. Acad. Sci. USA. 80:2723.

16. Monier, J. C., J. Brochier, A. Moreira, C. Sault, and B. Roux. 1984. Generation of hybridoma antibodies to double-stranded DNA from non-autoimmune BALB/c strain: studies on anti-idiotypic. Immunol. Lett. 8:61.

17. Eliat, D., M. Hochberg, J. Pumphrey, and S. Rudikoff. 1984. Monoclonal antibodies to DNA and RNA from NZB/NZW F1 mice: antigenic specificities and NH2-terminal amino acid sequences. J. Immunol. 133:489.

18. Kofler, R., D. J. Noonan, D. E. Levy, M. C. Wilson, N. P. H. Møller, F. J. Dixon, and A. N. Theofilopoulos. 1985. Genetic elements utilized for a murine lupus anti-DNA autoantibody are closely related to those for antibodies to exogenous antigens. J. Exp. Med. 161:in press.

19. Diamond, B., and M. D. Scharff. 1984. Somatic mutation of the T15 heavy chain gives rise to an antibody with autoantibody specificitly. Proc. Natl. Acad. Sci. USA. 81:5841.